NDA 020919 · Viatris
Geodon
Ziprasidone Mesylate · Intramuscular · Atypical Antipsychotic
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Jun 21, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
134
38 Phase 3, 2 recruiting
FAERS reports
17,662
12,204 serious, 1,238 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Jan 15, 2025.
GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3) ] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.3) ] . Schizophrenia • GEODON is indicated for the treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate) • GEODON is indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies (14.2) ] . • GEODON is indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies (14.2) ] . Acute Treatment of Agitation in Schizophrenia • GEODON intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate and who need...
Mechanism: The mechanism of action of ziprasidone in the treatment of the listed indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 21, 2002 Original approval · Type 3 - New Dosage Form ReviewLabelOther Important Information from FDA
1 products under this application
- GEODON · ZIPRASIDONE MESYLATE EQ 20MG BASE/VIAL · POWDER, INTRAMUSCULAR · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ziprasidone" as an intervention, any sponsor and status, largest first.
- Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00418171 · 18,239 participants · Start Feb 2002
Drug: Ziprasidone; Olanzapine · For: Schizophrenia
Sites: San Bernardino, California; ‘Aiea, Hawaii; Schaumburg, Illinois · 5 sites in all
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic AgitationStatus unknown
Yang FudeAcademic, hospital or other
NCT02935998 · 1,000 participants (planned) · Start Oct 2016 · Primary completion Dec 2017
Drug: Ziprasidone · For: Schizophrenia
Sites: Beijing, China
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic SubjectsPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00312494 · 680 participants · Start Apr 2006 · Primary completion Dec 2008
Drug: Placebo; Ziprasidone and 1 more · For: Bipolar Disorder
Sites: Dothan, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 66 sites in all
- Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaPivotal-lookingCompleted
Vanda PharmaceuticalsIndustry
NCT00254202 · 593 participants · Start Nov 18, 2005 · Primary completion Sep 26, 2006
Drug: Iloperidone; Ziprasidone and 1 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Anaheim, California; Cerritos, California · 42 sites in all
- Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)Pivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00280566 · 584 participants · Start Dec 2005 · Primary completion May 2008
Drug: Placebo; Ziprasidone Oral Capsule · For: Bipolar Mania; Bipolar Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 107 sites in all
- The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) StudyPivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT01211522 · 566 participants · Start Dec 14, 2011 · Primary completion Aug 28, 2017
Drug: Haloperidol; Ziprasidone and 1 more · For: Delirium; Impaired Cognition; Long Term Psychologic Disorders
Sites: Denver, Colorado; New Haven, Connecticut; Indianapolis, Indiana · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,438
- weight increased1,185
- diabetes mellitus1,004
- anxiety883
- type 2 diabetes mellitus859
- insomnia806
- depression792
- somnolence750
- fatigue727
- tardive dyskinesia707
- tremor699
- nausea682
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 559 |
| 2005 | 664 |
| 2006 | 718 |
| 2007 | 860 |
| 2008 | 438 |
| 2009 | 1,102 |
| 2010 | 2,777 |
| 2011 | 1,613 |
| 2012 | 1,060 |
| 2013 | 734 |
| 2014 | 612 |
| 2015 | 833 |
| 2016 | 867 |
| 2017 | 711 |
| 2018 | 643 |
| 2019 | 660 |
| 2020 | 619 |
| 2021 | 517 |
| 2022 | 474 |
| 2023 | 364 |
| 2024 | 290 |
| 2025 | 304 |
| 2026 | 243 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Geodon (Ziprasidone HCl)
2024 spending
$5.4M
Beneficiaries
316
2,605 claims
Per beneficiary
$16,960
$27.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,349,288 |
| 2021 | $7,824,572 |
| 2022 | $6,553,727 |
| 2023 | $6,284,899 |
| 2024 | $5,359,404 |
Part D: Geodon (Ziprasidone Mesylate)
2024 spending
$25K
Beneficiaries
44
129 claims
Per beneficiary
$558
$66.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $507,913 |
| 2021 | $128,621 |
| 2022 | $53,079 |
| 2023 | $20,855 |
| 2024 | $24,547 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. · Lancet 2019 · Research Support, Non-U.S. Gov't, Systematic Review
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, et al. · Lancet 2013 · Comparative Study, Meta-Analysis
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, et al. · Lancet Psychiatry 2020 · Comparative Study, Network Meta-Analysis
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.